Multiple Sclerosis

The FDA has granted breakthrough device designation to Quanterix Corp. for its Simoa neurofilament light chain plasma test, a prognostic aid that assesses risk for disease activity in patients with relapsing-remitting MS.

SEATTLE — Davorka Tomic, head of clinical development in neurology at Merck KGaA, spoke with Healio at the 2022 American Academy of Neurology annual meeting about multiple clinical trials for patients with MS.

SEATTLE — Black patients with MS demonstrated a higher rate of disability throughout their disease course compared with white MS patients, according to a presenter at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Fatigue is a frequent concern for patients with MS in the United Kingdom and has multiple predictors, according to a presenter at the 2022 American Academy of Neurology annual meeting.

High alcohol use was associated with more severe neurodegeneration and smoking was linked with greater probability of MS diagnosis, according to a U.K. study published in JAMA Network Open.

WEST PALM BEACH, Florida — BMI was significantly associated with functional disability in patients with MS, as were additional variables related to BMI, according to a study presented at ACTRIMS Forum.

WEST PALM BEACH, Florida — Genetically predicted levels of 25-hydroxyvitamin D were generally not associated with adverse disease outcomes in MS patients of European ancestry, according to a study presented at ACTRIMS Forum.

WEST PALM BEACH, Florida — The National Health and Nutrition Examination Survey Biological Age Index is a reliable predictor of multiple MS disability outcomes and progressive phenotypes, according to a study presented at ACTRIMS Forum.

WEST PALM BEACH, Florida — Physical activity levels and sleep correlated with psychological outcomes in MS, according to data presented at the ACTRIMS Forum.

WEST PALM BEACH, Fla. — The economic burden of MS in the United States, estimated to be more than $85 billion in 2019, is projected to rise to $105 billion by 2039, according to a study presented at ACTRIMS Forum.